Powerful Medical Breaks New Ground at AHA 2024, Winning Top Honors in Health Tech
On November 27, 2024, history was made at the American Heart Association (AHA) Health Tech Competition as Powerful Medical bagged two prestigious awards: the Best Science Startup and Overall Winner. This momentous achievement underscores the company's transformative contributions to cardiovascular healthcare with its cutting-edge AI-powered clinical platform, PMcardio.
The AHA competition serves as a stage for innovative solutions tackling critical issues in heart disease diagnostics and therapy. Competing against a pool of startups, Powerful Medical captured the attention of a discerning panel comprising esteemed physicians, scientists, and industry leaders with a compelling showcase of PMcardio and its OMI AI ECG model, which promises enhanced accuracy in cardiac assessments.
PMcardio, a CE-certified Class IIb EU MDR medical device, stands testament to Powerful Medical's commitment to improving clinical outcomes by providing fast and precise analyses of 12-lead ECGs for 39 different cardiovascular conditions. Having been deployed across 16 European countries, PMcardio has supported over 57,000 clinicians globally, impacting the management of more than 1.1 million patients thus far. The platform’s ability to streamline workflows is just one aspect of its growing reputation.
Dr. Robert Herman, the Chief Medical Officer at Powerful Medical, highlighted the platform's significance, expressing, "Our technology enables more precise detection of acute heart attacks, with the potential to prevent over 12,000 excess deaths annually in the US." This statistic emphasizes not just innovation but also the lifesaving implications of their technology.
At the AHA 2024 Scientific Sessions, the company also presented significant findings on the gender disparities in cardiac care and the role of AI in smartphone diagnostics, showcasing how their solutions adapt to the evolving healthcare landscape. The highlights included research on cath lab activation solutions and external validations of PMcardio that add layers of credibility to their claims of efficacy.
Martin Herman, CEO of Powerful Medical, articulated a vision of inclusivity within the healthcare system. "Winning both titles reflects our vision to build a healthcare system rooted in value-based care and equity. We aim for PMcardio to transform cardiovascular diagnostics, ensuring timely and quality care for patients, regardless of their demographic or geographic circumstances," Herman stated.
The rigorous evaluation process of the AHA Health Tech Competition, featuring a two-pitch format, assessed entrants on scientific impact and scalability in the business domain. Powerful Medical's compelling evidence of efficacy coupled with its scalable operational model addressing widespread issues like misdiagnosis and delayed treatments for heart attacks propelled it to victory.
This landmark achievement not only positions Powerful Medical among the forefront leaders in healthcare innovation but also sets the stage for further advancements. As the company gears up for its US expansion, it carries forward a robust deal pipeline, ongoing clinical studies, and anticipates FDA De Novo clearance soon. With a substantial $25 million Series A funding backing its initiatives, the future looks bright for PMcardio.
For more information about their groundbreaking work in cardiovascular health, visit Powerful Medical's website.
The AHA competition serves as a stage for innovative solutions tackling critical issues in heart disease diagnostics and therapy. Competing against a pool of startups, Powerful Medical captured the attention of a discerning panel comprising esteemed physicians, scientists, and industry leaders with a compelling showcase of PMcardio and its OMI AI ECG model, which promises enhanced accuracy in cardiac assessments.
PMcardio, a CE-certified Class IIb EU MDR medical device, stands testament to Powerful Medical's commitment to improving clinical outcomes by providing fast and precise analyses of 12-lead ECGs for 39 different cardiovascular conditions. Having been deployed across 16 European countries, PMcardio has supported over 57,000 clinicians globally, impacting the management of more than 1.1 million patients thus far. The platform’s ability to streamline workflows is just one aspect of its growing reputation.
Dr. Robert Herman, the Chief Medical Officer at Powerful Medical, highlighted the platform's significance, expressing, "Our technology enables more precise detection of acute heart attacks, with the potential to prevent over 12,000 excess deaths annually in the US." This statistic emphasizes not just innovation but also the lifesaving implications of their technology.
At the AHA 2024 Scientific Sessions, the company also presented significant findings on the gender disparities in cardiac care and the role of AI in smartphone diagnostics, showcasing how their solutions adapt to the evolving healthcare landscape. The highlights included research on cath lab activation solutions and external validations of PMcardio that add layers of credibility to their claims of efficacy.
Martin Herman, CEO of Powerful Medical, articulated a vision of inclusivity within the healthcare system. "Winning both titles reflects our vision to build a healthcare system rooted in value-based care and equity. We aim for PMcardio to transform cardiovascular diagnostics, ensuring timely and quality care for patients, regardless of their demographic or geographic circumstances," Herman stated.
The rigorous evaluation process of the AHA Health Tech Competition, featuring a two-pitch format, assessed entrants on scientific impact and scalability in the business domain. Powerful Medical's compelling evidence of efficacy coupled with its scalable operational model addressing widespread issues like misdiagnosis and delayed treatments for heart attacks propelled it to victory.
This landmark achievement not only positions Powerful Medical among the forefront leaders in healthcare innovation but also sets the stage for further advancements. As the company gears up for its US expansion, it carries forward a robust deal pipeline, ongoing clinical studies, and anticipates FDA De Novo clearance soon. With a substantial $25 million Series A funding backing its initiatives, the future looks bright for PMcardio.
For more information about their groundbreaking work in cardiovascular health, visit Powerful Medical's website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.